评估依拉环素对近期临床分离的广泛厌氧菌的活性。
Evaluation of the Activity of Eravacycline against a Broad Spectrum of Recent Clinical Anaerobic Isolates.
机构信息
Department of Medicine, Tufts Medical Center, Boston, Massachusetts, USA
Department of Medicine, Tufts Medical Center, Boston, Massachusetts, USA.
出版信息
Antimicrob Agents Chemother. 2018 Apr 26;62(5). doi: 10.1128/AAC.02206-17. Print 2018 May.
Abstract
The novel fluorocycline antibiotic eravacycline is in development for use in the treatment of serious infections caused by susceptible and multidrug-resistant (MDR) aerobic and anaerobic Gram-negative and Gram-positive pathogens. Eravacycline and 11 comparator antibiotics were tested against recent anaerobic clinical isolates, including MDR spp. and Eravacycline was potent against all the isolates tested, including strains with tetracycline-specific resistance determinants and MDR anaerobic pathogens resistant to carbapenems and/or β-lactam-β-lactamase inhibitor combinations.
摘要
新型氟环素类抗生素依拉环素正在开发中，用于治疗由敏感和多药耐药（MDR）需氧和厌氧革兰氏阴性和革兰氏阳性病原体引起的严重感染。依拉环素和 11 种对照抗生素对最近的厌氧临床分离株进行了测试，包括 MDR spp.和 依拉环素对所有测试的分离株均具有强大的抗菌活性，包括具有四环素特异性耐药决定因素和对碳青霉烯类和/或β-内酰胺-酶抑制剂组合耐药的多药耐药厌氧病原体的菌株。
相似文献
1
Evaluation of the Activity of Eravacycline against a Broad Spectrum of Recent Clinical Anaerobic Isolates.
Antimicrob Agents Chemother. 2018 Apr 26;62(5). doi: 10.1128/AAC.02206-17. Print 2018 May.
2
Antimicrobial activity of eravacycline and other comparative agents on aerobic and anaerobic bacterial pathogens in Taiwan: A clinical microbiological study.
J Glob Antimicrob Resist. 2024 Jun;37:93-99. doi: 10.1016/j.jgar.2024.03.014. Epub 2024 Mar 27.
3
Eravacycline, a newly approved fluorocycline.
Eur J Clin Microbiol Infect Dis. 2019 Oct;38(10):1787-1794. doi: 10.1007/s10096-019-03590-3. Epub 2019 Jun 7.
4
Antimicrobial susceptibility of clinically isolated anaerobic bacteria in a University Hospital Centre Split, Croatia in 2013.
Anaerobe. 2015 Feb;31:31-6. doi: 10.1016/j.anaerobe.2014.10.010. Epub 2014 Dec 3.
5
Activity of Eravacycline against Gram-Negative Bacilli Isolated in Clinical Laboratories Worldwide from 2013 to 2017.
Antimicrob Agents Chemother. 2020 Feb 21;64(3). doi: 10.1128/AAC.01699-19.
6
In vitro susceptibility of β-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE) to eravacycline.
J Antibiot (Tokyo). 2016 Aug;69(8):600-4. doi: 10.1038/ja.2016.73. Epub 2016 Jun 29.
7
Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens.
Antimicrob Agents Chemother. 2013 Nov;57(11):5548-58. doi: 10.1128/AAC.01288-13. Epub 2013 Aug 26.
8
In vitro activity of eravacycline and comparator antimicrobials against 143 recent strains of Bacteroides and Parabacteroides species.
Anaerobe. 2018 Aug;52:122-124. doi: 10.1016/j.anaerobe.2018.06.016. Epub 2018 Jul 4.
9
Development of Resistance to Eravacycline by Klebsiella pneumoniae and Collateral Sensitivity-Guided Design of Combination Therapies.
Microbiol Spectr. 2022 Oct 26;10(5):e0139022. doi: 10.1128/spectrum.01390-22. Epub 2022 Aug 16.
10
Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent.
Drugs. 2016 Apr;76(5):567-88. doi: 10.1007/s40265-016-0545-8.
引用本文的文献
1
Novel Antibacterial Approaches and Therapeutic Strategies.
Antibiotics (Basel). 2025 Apr 15;14(4):404. doi: 10.3390/antibiotics14040404.
2
activities of eravacycline against clinical bacterial isolates: a multicenter study in Guangdong, China.
Front Microbiol. 2024 Nov 18;15:1504013. doi: 10.3389/fmicb.2024.1504013. eCollection 2024.
3
Alternatives Therapeutic Approaches to Conventional Antibiotics: Advantages, Limitations and Potential Application in Medicine.
Antibiotics (Basel). 2022 Dec 16;11(12):1826. doi: 10.3390/antibiotics11121826.
4
In Vitro Antimicrobial Susceptibility Profiles of Gram-Positive Anaerobic Cocci Responsible for Human Invasive Infections.
Microorganisms. 2021 Aug 4;9(8):1665. doi: 10.3390/microorganisms9081665.
5
New Antibiotics for Multidrug-Resistant Bacterial Strains: Latest Research Developments and Future Perspectives.
Molecules. 2021 May 2;26(9):2671. doi: 10.3390/molecules26092671.
6
In vitro activity of eravacycline against common ribotypes of Clostridioides difficile.
J Antimicrob Chemother. 2020 Oct 1;75(10):2879-2884. doi: 10.1093/jac/dkaa289.
7
Antimicrobial Resistance in ESKAPE Pathogens.
Clin Microbiol Rev. 2020 May 13;33(3). doi: 10.1128/CMR.00181-19. Print 2020 Jun 17.
8
Treatment Options for Colistin Resistant : Present and Future.
J Clin Med. 2019 Jun 28;8(7):934. doi: 10.3390/jcm8070934.
9
The Efficacy and Safety of Eravacycline in the Treatment of Complicated Intra-Abdominal Infections: A Systemic Review and Meta-Analysis of Randomized Controlled Trials.
J Clin Med. 2019 Jun 17;8(6):866. doi: 10.3390/jcm8060866.
10
Clinical Pharmacokinetics and Pharmacodynamics of Eravacycline.
Clin Pharmacokinet. 2019 Sep;58(9):1149-1153. doi: 10.1007/s40262-019-00767-z.
本文引用的文献
1
Trends in antimicrobial resistance among Bacteroides species and Parabacteroides species in the United States from 2010-2012 with comparison to 2008-2009.
Anaerobe. 2017 Feb;43:21-26. doi: 10.1016/j.anaerobe.2016.11.003. Epub 2016 Nov 17.
2
Assessing the Efficacy and Safety of Eravacycline vs Ertapenem in Complicated Intra-abdominal Infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) Trial: A Randomized Clinical Trial.
JAMA Surg. 2017 Mar 1;152(3):224-232. doi: 10.1001/jamasurg.2016.4237.
3
Eravacycline Is Active against Bacterial Isolates Expressing the Polymyxin Resistance Gene mcr-1.
Antimicrob Agents Chemother. 2016 Oct 21;60(11):6989-6990. doi: 10.1128/AAC.01646-16. Print 2016 Nov.
4
In vitro susceptibility of β-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE) to eravacycline.
J Antibiot (Tokyo). 2016 Aug;69(8):600-4. doi: 10.1038/ja.2016.73. Epub 2016 Jun 29.
5
In Vitro Activity of Eravacycline against Carbapenem-Resistant Enterobacteriaceae and Acinetobacter baumannii.
Antimicrob Agents Chemother. 2016 May 23;60(6):3840-4. doi: 10.1128/AAC.00436-16. Print 2016 Jun.
6
U.S.-Based National Sentinel Surveillance Study for the Epidemiology of Clostridium difficile-Associated Diarrheal Isolates and Their Susceptibility to Fidaxomicin.
Antimicrob Agents Chemother. 2015 Oct;59(10):6437-43. doi: 10.1128/AAC.00845-15. Epub 2015 Aug 3.
7
Activity of eravacycline against Enterobacteriaceae and Acinetobacter baumannii, including multidrug-resistant isolates, from New York City.
Antimicrob Agents Chemother. 2015 Mar;59(3):1802-5. doi: 10.1128/AAC.04809-14. Epub 2014 Dec 22.
8
Phase 2, randomized, double-blind study of the efficacy and safety of two dose regimens of eravacycline versus ertapenem for adult community-acquired complicated intra-abdominal infections.
Antimicrob Agents Chemother. 2014;58(4):1847-54. doi: 10.1128/AAC.01614-13. Epub 2013 Dec 16.
9
Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens.
Antimicrob Agents Chemother. 2013 Nov;57(11):5548-58. doi: 10.1128/AAC.01288-13. Epub 2013 Aug 26.
10
Target- and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic.
Antimicrob Agents Chemother. 2012 May;56(5):2559-64. doi: 10.1128/AAC.06187-11. Epub 2012 Feb 21.
Zotero 插件